logo
Even a small amount of processed meat increases health risks, study finds

Even a small amount of processed meat increases health risks, study finds

Globe and Mail21-07-2025
There's abundant evidence that eating lots of processed meat is linked to an increased risk of heart disease, Type 2 diabetes and, most notably, colorectal cancer.
According to the World Cancer Research Fund, there is no intake level of processed meat that does not pose a colorectal cancer risk.
Now, findings from a large review of research add to the increasing body of evidence that underscores the harmful health effects of processed meat.
Here's what to know about the latest research, plus why you don't have to completely abandon your summer hot dog.
Processed meat refers to meat – red meat and poultry – that has been preserved by smoking, curing, salting or the addition of chemical preservatives.
Ham, bacon, pastrami, salami, deli meats, beef jerky, sausages and hot dogs, for example, are processed meats.
Commercially produced burgers can also fall into the processed meat category if they're preserved with chemicals.
For the study, published June 30 in the journal Nature Medicine, researchers analyzed dozens of previous studies that investigated the relationship between processed meat and risk of colorectal cancer, Type 2 diabetes and coronary heart disease.
To assess the connection between processed meat consumption and colorectal cancer, 18 studies involving 2,678,052 participants were reviewed.
All studies controlled for age and sex and most adjusted for other risk factors including body mass index, smoking, alcohol intake, calorie intake and physical activity.
On average, eating 50 grams of processed meat a day – versus none – was tied to a 26 per cent increased risk of developing colorectal cancer.
A healthy diet helps with heart health, even without weight loss
For perspective, 50 g of processed meat is equivalent to roughly four slices of cooked bacon, three slices of packaged deli ham or two-thirds of a jumbo-sized hot dog (75 g). A standard-sized hot dog typically weighs 38 g.
To examine processed meat intake and Type 2 diabetes risk, 16 studies with a total of 1,115,885 participants were reviewed. The studies accounted for other influences such as age, sex, body mass index and dietary factors.
The risk of developing Type 2 diabetes was, on average, 30 per cent higher for a daily intake of 50 g of processed meat compared to none.
The researchers also conservatively estimated that consuming processed meat within the range of 0.6 to 57 g per day, compared to consuming none, was associated with, on average, at least a 7 per cent higher risk of colorectal cancer and an 11 per cent higher risk of Type 2 diabetes.
The risk of colorectal cancer and Type 2 diabetes rose as consumption increased.
Notably, health risks increased the fastest at low intake levels, suggesting there is no 'safe' amount of processed meat with respect to colorectal cancer or Type 2 diabetes risk.
A regular intake of processed meat was also tied to an increased risk of coronary heart disease. This finding, however, wasn't statistically significant, meaning it could have occurred by chance.
A high intake of processed meat is thought to increase visceral fat (deep abdominal fat) and inflammation.
Processed meat is also typically high in sodium and saturated fat.
As well, chemical compounds in cooked processed meat called heterocyclic amines and polycyclic aromatic hydrocarbons have been shown to induce tumours in experimental studies.
Heme iron in processed red meat may promote colon tumours by stimulating the formation of carcinogenic N-nitroso compounds. Processed meat can also contain nitrate additives, which can contribute to the formation of N-nitroso compounds in the body.
The new study also analyzed previous studies that examined the link between chronic disease risk and sugar-sweetened beverages (SSB), which include pop, iced tea, lemonade, sports drinks, energy drinks and sugary coffee drinks.
Consuming 250 g (eight ounces) of SSB per day, compared to none, was associated with a 20 per cent higher risk of developing Type 2 diabetes and a 7 per cent greater risk of developing coronary heart disease.
A high intake of added sugars, especially in liquid form, contributes to elevated inflammatory markers in the bloodstream and accumulation of harmful visceral fat.
The analysis included studies that were observational and, as such, found associations between diet and chronic disease. The findings don't prove there is a causal relationship.
As well, participants self-reported their dietary intake. Memory errors can occur when trying to recall long-term food intake.
Despites these limitations, the new findings are very consistent with prior research.
They reinforce recommendations to avoid or minimize the consumption of processed meat and sugar-sweetened drinks to improve health.
If processed meat and/or sugary drinks are a regular part of your diet, it's wise to cut back.
Remember, too, it's your overall dietary pattern that matters when it comes to health.
A diet that's plentiful in vegetables, fruits, whole grains, nuts and pulses can, if you like, include the occasional hot dog.
Leslie Beck, a Toronto-based private practice dietitian, is director of food and nutrition at Medcan. Follow her on X @LeslieBeckRD
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hemophilia Pipeline Outlook Report 2025: Key 80+ Companies and Breakthrough Therapies Shaping the Future Landscape
Hemophilia Pipeline Outlook Report 2025: Key 80+ Companies and Breakthrough Therapies Shaping the Future Landscape

Globe and Mail

time8 hours ago

  • Globe and Mail

Hemophilia Pipeline Outlook Report 2025: Key 80+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight's, 'Hemophilia Pipeline Insight, 2025,' report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Hemophilia Pipeline Outlook Report Key Takeaways from the Hemophilia Pipeline Report In July 2025, Novo Nordisk A/S announced a study is looking at how safe it is to switch from emicizumab to Mim8, in people with haemophilia A. Mim8 is a new medicine that is used to prevent bleeding episodes in people with haemophilia A. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). Mim8 will be injected under the skin using a pen-injector either once every week, once every two weeks or once every month. The participants will be trained in using the pen injector. In July 2025, Pfizer announced a study to establish baseline prospective efficacy data of current FIX prophylaxis replacement therapy in the usual care setting of hemophilia B subjects, who are negative for nAb to AAV-Spark100, prior to the Phase 3 gene therapy study. In July 2025, Regeneron Pharmaceuticals announced a study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately severe hemophilia B. This study is researching an experimental gene insertion therapy (the adding of a gene into your DNA) called REGV131-LNP1265, also called the "study drug". Gene insertion therapy aims to teach the body how to produce clotting factor long-term, without the need for factor replacement therapy. DelveInsight's Hemophilia pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Hemophilia treatment. The leading Hemophilia Companies such as Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others. Promising Hemophilia Pipeline Therapies such as NNC0365-3769 (Mim8) PPX, Mim8, STSP-0601 for Injection, Fitusiran, Marstacimab, Fitusiran, BPA prophylaxis, Concizumab, PF-06741086 and others. Discover how the Hemophilia treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Hemophilia Clinical Trials and Studies Hemophilia Emerging Drugs Profile SerpinPC: Centessa Pharmaceuticals SerpinPC, a specific inhibitor of activated protein C (APC), for the treatment of hemophilia A and hemophilia B. SerpinPC has been observed to be well-tolerated in the clinical setting, associated with promising reductions in bleeding rates, and has PK suitable for infrequent subcutaneous dosing without the need for factor replacement. SerpinPC has human genetic target validation and established proof of concept Phase 2a clinical data. Fitusiran: Alnylam Pharmaceuticals Fitusiran (ALN-AT3) is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT) in development for the treatment of hemophilia and rare bleeding disorders (RBDs) by their collaborators at Sanofi Genzyme. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Hemophilia. ASC 618: ASC Therapeutics ASC618 is an AAV8-based gene therapy for the treatment of hemophilia A, affecting approximately 1 of every 5000 live-born males. ASC618 incorporates a novel liver-specific promoter and a bioengineered, codon-optimized B domain-deleted FVIII variant; in preclinical studies, ASC618 exhibits at least a 10-fold increase in the biosynthesis and secretion of FVIII compared with native human FVIII bioengineered gene constructs. ASC618 has the potential to increase durability of clotting factor biosynthesis and secretion by minimizing cellular stress and induction of the unfolded protein response, which may lead to diminished FVIII production from liver cells. ASC Therapeutics will conduct a phase 1/2 clinical trial to evaluate the safety, tolerability, and preliminary efficacy of ASC618. The program received IND clearance from the U.S. Food and Drug Administration. The Hemophilia Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Hemophilia with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia Treatment. Hemophilia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Hemophilia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemophilia market. Get a detailed analysis of the latest innovations in the Hemophilia Pipeline. Explore DelveInsight's expert-driven report today! @ Hemophilia Unmet Needs Hemophilia Companies Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others. Hemophilia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intra-articular Intraocular Intrathecal Intravenous Ophthalmic Oral Parenteral Subcutaneous Topical Transdermal Products have been categorized under various Molecule types such as Oligonucleotide Peptide Small molecule Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key Hemophilia Developments @ Hemophilia Market Drivers and Barriers, and Future Perspectives Scope of the Hemophilia Pipeline Report Coverage- Global Hemophilia Companies- Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others. Hemophilia Pipeline Therapies- NNC0365-3769 (Mim8) PPX, Mim8, STSP-0601 for Injection, Fitusiran, Marstacimab, Fitusiran, BPA prophylaxis, Concizumab, PF-06741086 and others. Hemophilia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Hemophilia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Hemophilia drug development? Find out in DelveInsight's exclusive Pipeline Report—access it now! @ Hemophilia Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Hemophilia: Overview Pipeline Therapeutics Therapeutic Assessment Hemophilia– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Fitusiran: Alnylam Pharmaceuticals Mid Stage Products (Phase II) SerpinPC: Centessa Pharmaceuticals Drug profiles in the detailed report….. Early Stage Products (Phase I) Drug name: Company Name Preclinical and Discovery Stage Products Drug name: Company Name Inactive Products Hemophilia Key Companies Hemophilia Key Products Hemophilia- Unmet Needs Hemophilia- Market Drivers and Barriers Hemophilia- Future Perspectives and Conclusion Hemophilia Analyst Views Hemophilia Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store